GT200700062A - USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS - Google Patents

USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS

Info

Publication number
GT200700062A
GT200700062A GT200700062A GT200700062A GT200700062A GT 200700062 A GT200700062 A GT 200700062A GT 200700062 A GT200700062 A GT 200700062A GT 200700062 A GT200700062 A GT 200700062A GT 200700062 A GT200700062 A GT 200700062A
Authority
GT
Guatemala
Prior art keywords
amina
anticancerigen
agents
useful derivatives
transformation
Prior art date
Application number
GT200700062A
Other languages
Spanish (es)
Inventor
Matthew Stephen Corbett
Goss Stryker Kauffman
Kevin Daniel Freeman-Cook
Blaise Scott Lippa
Michael Joseph Luzzio
Joel Morris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200700062A publication Critical patent/GT200700062A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN LA QUE A,L,R1,R2,R5,R6,U, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS DERIVADOS DE AMINA IMPIDEN LA TRANSFORMACION DE UNA PARTE DEL ADN DE UNA CELULA EN UN ONCOGEN QUE PUEDE LLEGAR A SER CANCEROSA A NIVEL DE LAS QUINASAS ABERRANTES CAPACES DE CAUSAR TRANSFORMACION CELULAR POR LO QUE SON DE UTILIDAD EN TRASTORNOS HIPERPROLIFERATIVOS TALES COMO EL CANCER. T2007THE PRESENT INVENTION CONCERNS COMPOUNDS OF GENERAL FORMULA I IN WHICH A, L, R1, R2, R5, R6, U, ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. THESE COMPOUNDS DERIVED FROM AMINA PREVENT THE TRANSFORMATION OF A PART OF THE DNA OF A CELL IN AN ONCOGEN THAT CAN BECOME CANCEROSE AT THE LEVEL OF ABERRANT KINASES ABLE TO CAUSE CELL TRANSFORMATION, WHICH THE HYPERTARCER CANCELLATION IS USEFUL. T2007

GT200700062A 2006-07-26 2007-07-24 USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS GT200700062A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82044106P 2006-07-26 2006-07-26

Publications (1)

Publication Number Publication Date
GT200700062A true GT200700062A (en) 2008-08-08

Family

ID=38963178

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200700062A GT200700062A (en) 2006-07-26 2007-07-24 USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS

Country Status (7)

Country Link
AR (1) AR062050A1 (en)
CL (1) CL2007002188A1 (en)
GT (1) GT200700062A (en)
PE (1) PE20080689A1 (en)
TW (1) TW200817408A (en)
UY (1) UY30499A1 (en)
WO (1) WO2008012635A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103288753A (en) 2006-07-06 2013-09-11 阵列生物制药公司 Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
SI2054418T1 (en) 2006-07-06 2012-02-29 Array Biopharma Inc Dihydrothieno pyrimidines as akt protein kinase inhibitors
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
UA99284C2 (en) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані P70 s6 kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5608097B2 (en) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド Pyrrolopyridine as a kinase inhibitor
CA2711741A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ586720A (en) 2008-01-09 2012-11-30 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
AR071717A1 (en) 2008-05-13 2010-07-07 Array Biopharma Inc PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER.
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
AR074072A1 (en) 2008-11-11 2010-12-22 Lilly Co Eli COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
ES2539620T3 (en) 2008-12-19 2015-07-02 Cephalon, Inc. Pyrrolotriazine as an inhibitor of ALK and JAK2
DE102009005193A1 (en) * 2009-01-20 2010-07-22 Merck Patent Gmbh Novel heterocyclic compounds as MetAP-2 inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
PT2473049T (en) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Bruton's tyrosine kinase inhibitors
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
ES2621857T3 (en) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combination of control point kinase 1 inhibitors and WEE1 kinase inhibitors
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
PT2694072T (en) 2011-04-01 2018-02-26 Genentech Inc Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
AU2012308681B2 (en) * 2011-09-12 2017-07-13 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
AR091273A1 (en) 2012-06-08 2015-01-21 Biogen Idec Inc PYRIMIDINYL TIROSINE KINASE INHIBITORS
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
RS56924B9 (en) 2013-04-19 2019-09-30 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MX2017010673A (en) 2015-02-20 2018-03-21 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PT3436461T (en) 2016-03-28 2024-01-23 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
BR112019001158A2 (en) 2016-07-21 2019-04-30 Biogen Ma, Inc. succinate forms and bruton tyrosine kinase inhibitor compositions
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (en) 2019-10-14 2022-07-19 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CR20220285A (en) 2019-12-04 2022-10-27 Incyte Corp Derivatives of an fgfr inhibitor
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors

Also Published As

Publication number Publication date
WO2008012635A3 (en) 2008-05-08
UY30499A1 (en) 2008-02-29
PE20080689A1 (en) 2008-06-14
TW200817408A (en) 2008-04-16
CL2007002188A1 (en) 2008-02-01
WO2008012635A2 (en) 2008-01-31
AR062050A1 (en) 2008-08-10

Similar Documents

Publication Publication Date Title
GT200700062A (en) USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS
DOP2006000102A (en) PURINA DERIVATIVES
GT200500103A (en) 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS
GT200300296A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
GT200300150A (en) KINASE INHIBITORS
MA32319B1 (en) Triazine derivatives are useful as kinase inhibitors of mtor and ft3
GT200600181A (en) DERIVATIVES OF REPLACED AMIDA AND METHODS OF USE
CR9048A (en) ANILINO-PYRIMIDINE ANALOGS
GT200600356A (en) FUNGICIDE BLENDS CONTAINING SUBSTITUTED ANILIDES OF ACID 1-METHYLPIRAZOL-4-ILCARBOXILICO.
GT200600430A (en) CARBOXYAMINE COMPOUNDS AND SAME USE METHODS
PE20090511A1 (en) IMIDAZOPYRIDINONES
JO2910B1 (en) Organic Compounds
CR20110620A (en) DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZO-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINES AS IHNIBITORS OF THE JANUS KINASE
GT200400032A (en) NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
GT200600024A (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
GT200600339A (en) MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
ECSP11010880A (en) ORGANIC COMPOUNDS
GT200700039A (en) TRIAZOLOPIRAZINE DERIVATIVES
GT200500101A (en) METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS
GT200300177A (en) COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES
GT200600030A (en) 2-PHENYL-INDOLES AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
PE20151537A1 (en) BIS (DIFLUOROMETHYL) PYRAZOLES AS FUNGICIDES
GT200300087A (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
PA8667201A1 (en) NEW PHARMACEUTICAL COMPOUNDS
GT200600422A (en) CARBOXAMIDE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC RECEIVER